about
Alpha emitter radium-223 and survival in metastatic prostate cancerA randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer.Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.Clinical significance of androgen secretion disorders in men with a malignancy.Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)Dynamics of hormonal disorders following unilateral orchiectomy for a testicular tumor.Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.Does pharmacological castration as adjuvant therapy for prostate cancer after radiotherapy affect anxiety and depression levels, cognitive functions and quality of life?Prognostic factors in patients undergoing lymphadenectomy for squamous cell carcinoma of the penis.Radiotherapy in testicular germ cell tumours - a literature review.Serous Carcinoma of the Uterine Cervix, an Extremely Rare Aggressive Entity: A Literature Review.Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.The quality of life and hormonal disturbances in testicular cancer survivors in Cisplatin era.Contemporary treatment of metastatic renal cell carcinomaTesticular teratomas: a growing problem?Recovery of dendritic cell counts and function in peripheral blood of cancer patients after chemotherapyIntravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancerOlaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
P50
Q29617472-A068E346-082A-4596-BEC5-FD6A0D45CCB7Q33411548-D83C1099-6678-4A55-9001-556D9F814B64Q33443616-63E62BE5-6C66-49BF-8AC5-E2CFAD17FAE7Q33840617-0D7086BF-4565-4185-9A64-1F2A7A1DA64EQ36627206-0422D007-9933-4F3C-A613-175ED4DE104EQ37742265-AA9F56D4-142D-425F-B409-ED8E9883A3CDQ38212374-0B9BD5EE-9FAC-4DD7-A748-7CD0D4297B97Q44473719-BA3DD678-6A4C-41F8-89C0-DCB7EFF0A3FEQ44543160-3B282421-35F5-45AB-ABE0-359917A82B06Q47120992-173FA66C-9BD9-4384-AF95-C1115436C5DEQ48515431-39597DEC-0DCF-4BE1-A549-0423472545AFQ53041535-C0CEC8BD-C331-4A4D-899D-1B7C06905480Q53189795-847AAEAA-53A5-4421-B21C-212217CC75ABQ58111735-BA0C4B88-E6B2-44E8-8B1E-03B7CDDC0013Q58115367-EE4B7D6A-8C0B-43C7-8AB3-BC58FE3CE259Q74596275-519A01B4-0F8D-423E-AD7D-CCA97DFEAC00Q80513021-CE07D5AE-617D-4F9B-B5DF-3C17F50F28BFQ89029416-34EED053-BEA1-4135-9AAE-4671706A6E8B
P50
description
Forscher
@de
Polish researcher
@en
chercheur
@fr
investigador
@es
polski naukowiec
@pl
taighdeoir Polannach
@ga
wetenschapper
@nl
研究者
@zh
name
Paweł Wiechno
@ast
Paweł Wiechno
@ca
Paweł Wiechno
@de
Paweł Wiechno
@en
Paweł Wiechno
@es
Paweł Wiechno
@fr
Paweł Wiechno
@ga
Paweł Wiechno
@gl
Paweł Wiechno
@it
Paweł Wiechno
@nl
type
label
Paweł Wiechno
@ast
Paweł Wiechno
@ca
Paweł Wiechno
@de
Paweł Wiechno
@en
Paweł Wiechno
@es
Paweł Wiechno
@fr
Paweł Wiechno
@ga
Paweł Wiechno
@gl
Paweł Wiechno
@it
Paweł Wiechno
@nl
altLabel
Pawel Wiechno
@en
prefLabel
Paweł Wiechno
@ast
Paweł Wiechno
@ca
Paweł Wiechno
@de
Paweł Wiechno
@en
Paweł Wiechno
@es
Paweł Wiechno
@fr
Paweł Wiechno
@ga
Paweł Wiechno
@gl
Paweł Wiechno
@it
Paweł Wiechno
@nl
P214
P1153
6508147504
P1412
P1559
Paweł Wiechno
@pl
P21
P214
P27
P31
P3124
P496
0000-0002-4894-3273
P735
P7859
viaf-306438603